$CRL

Creamer Victoria L sold $1.1M of CRL

Creamer Victoria L (EVP & Chief People Officer) sold 4,179 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $259.16 ($1.08M total) on 2026-08-06.

Original reporting
SEC EDGAR · Creamer Victoria L
Published Aug 10, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
medium confidence
Mentioned
$CRL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale by an EVP and Chief People Officer, including share count, price, and post-transaction holdings.

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying operational or financial update in the text.

03

What to watch

The article does not state whether the sale was part of a broader pattern, nor does it provide context like option exercises, tax planning, or other concurrent transactions.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 after-hours; reflects sale dated 2026-08-06

Background

The article is a SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc.

Company-level read

Ticker impact

$CRLNeutralMedium confidence
Context

Charles River Laboratories insider Victoria L Creamer sold 4,179 shares for about $1.08M at $259.16/share via an open-market sale.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than new company fundamentals.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no accompanying corporate news, guidance, or operational catalyst.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or personal liquidity needs, so the signal may be noise rather than bearish information.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Creamer Victoria L

    EVP & Chief People Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

$CRLMed

Charles River Laboratories at 2026 Global Healthcare Conference: growth builds

Charles River Laboratories (CRL) reported growth at the 2026 Global Healthcare Conference, with CEO Birgit Statham and CFO Glenn Sblendorio highlighting momentum in key segments. The company raised full-year organic growth and EPS guidance, citing stronger bookings in Discovery and Safety Assessment and improving margins in Manufacturing Support. Management also noted progress in stabilizing the non-human primate supply chain. However, they cautioned that recent strength may not sustain at the c

$CRLMedAI 8/10

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River Laboratories (CRL) is well-positioned for growth due to strong research-model demand and portfolio streamlining. The company's DSA segment shows improving demand, bookings, and backlog. CRL stock has surged 79% over the past year, outperforming its industry and the S&P 500. The company has a market cap of $13.92 billion and an earnings yield of 3.9%. However, mixed demand trends and NHP-related cost volatility remain risks. The Zacks Consensus Estimate for CRL’s 2026 earnings has i

$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.